Seeking Alpha

Osiris Therapeutics (OSIR) surges another 12.9% following the approval in New Zealand last week...

Osiris Therapeutics (OSIR) surges another 12.9% following the approval in New Zealand last week of Prochymal, the company's stem-cell therapy for acute graft-vs-host disease in children who have undergone bone marrow transplants. (previous)
Comments (2)
  • hmeltin
    , contributor
    Comments (2) | Send Message
     
    It seems the stock will go at least to 18 until it hits technical resistance.
    18 Jun 2012, 05:47 PM Reply Like
  • luismina
    , contributor
    Comments (2) | Send Message
     
    it will go beyond 18 when OSIR go global .more power OSIR!!
    24 Jun 2012, 10:22 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs